Close

Takeda announces availability of type 2 diabetes drugs in US

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

Projected Growth of Injectable Drug Market To $1139B By 2029

According to a recent analysis released by MarketsandMarkets, the...

How To Select A CDMO: Focus On Client-Centered Approach

When it comes to the pharmaceutical sector, choosing the...

Navigating Pharma Market Growth: CDMO Strategies For 2025

By the year 2025, it is projected that the...

Takeda Pharmaceutical Company has announced the availability of NESINA (alogliptin) and fixed-dose combinations KAZANO (alogliptin and metformin HCl) and OSENI (alogliptin and pioglitazone) by prescription in the US.

The FDA approved medications are indicated as an addition to diet and exercise for the treatment of type 2 diabetes.

Takeda Pharmaceuticals USA diabetes and obesity marketing senior director Jennifer Greeby said, “The availability of NESINA, KAZANO and OSENI marks an important milestone in Takeda’s commitment to patients living with type 2 diabetes, and provides new options for physicians.”

The dipeptidyl peptidase-4 inhibitor (DPP-4i), NESINA, is designed to slow the inactivation of incretin hormones glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic peptide (GIP).

Combination of alogliptin with metformin HCl, KAZANO, is an anti-diabetes medication formulated in a single tablet in addition to single tablet regeime OSENI that combines alogliptin with the thiazolidinedione (TZD) pioglitazone.

 

Latest stories

Related stories

Projected Growth of Injectable Drug Market To $1139B By 2029

According to a recent analysis released by MarketsandMarkets, the...

How To Select A CDMO: Focus On Client-Centered Approach

When it comes to the pharmaceutical sector, choosing the...

Navigating Pharma Market Growth: CDMO Strategies For 2025

By the year 2025, it is projected that the...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back